Champions Oncology (NASDAQ:CSBR) Share Price Breaks Below 200 Day Moving Average – Here’s Why

Champions Oncology, Inc. (NASDAQ:CSBR)’s stock price passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $5.76 and traded as low as $4.94. Champions Oncology shares last traded at $5.29, with a volume of 11,310 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Champions Oncology from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, September 16th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Champions Oncology Stock Down 2.9%

The stock has a market capitalization of $67.86 million, a price-to-earnings ratio of -60.94 and a beta of 0.40. The company’s fifty day simple moving average is $5.27 and its 200 day simple moving average is $5.75.

Champions Oncology (NASDAQ:CSBR) last posted its earnings results on Thursday, September 10th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Champions Oncology had a negative net margin of 1.82% and a negative return on equity of 25.77%. The company had revenue of $15.23 million during the quarter, compared to analysts’ expectations of $15.04 million.

Hedge Funds Weigh In On Champions Oncology

An institutional investor recently bought a new position in Champions Oncology stock. Bank of New York Mellon Corp acquired a new position in shares of Champions Oncology, Inc. (NASDAQ:CSBR) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 21,614 shares of the biotechnology company’s stock, valued at approximately $133,000. Bank of New York Mellon Corp owned 0.16% of Champions Oncology at the end of the most recent reporting period. Hedge funds and other institutional investors own 41.30% of the company’s stock.

Champions Oncology Company Profile

Champions Oncology, Inc is a biotechnology company that provides translational oncology services and data-driven solutions for cancer research and drug development. The company works with pharmaceutical and biotechnology organizations to help evaluate potential cancer therapies, identify responsive patient populations and support precision-medicine programs.

Its offerings include patient-derived xenograft and other tumor models, in vitro and in vivo testing, genomic and molecular profiling, biomarker analysis, and oncology data analytics.